Markowitz, Geoffrey J. http://orcid.org/0000-0003-3915-8078
Ban, Yi
Tavarez, Diamile A.
Yoffe, Liron http://orcid.org/0000-0002-3040-8205
Podaza, Enrique
He, Yongfeng
Martin, Mitchell T.
Crowley, Michael J. P.
Sandoval, Tito A. http://orcid.org/0000-0003-2705-5282
Gao, Dingcheng http://orcid.org/0000-0002-3903-2603
Martin, M. Laura http://orcid.org/0000-0001-9359-5856
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
Cubillos-Ruiz, Juan R. http://orcid.org/0000-0002-4267-4893
McGraw, Timothy E. http://orcid.org/0000-0001-9748-263X
Altorki, Nasser K. http://orcid.org/0000-0001-9754-9945
Mittal, Vivek http://orcid.org/0000-0002-4764-7413
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5T32CA203702)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (KL2-TR-002385)
Article History
Received: 2 August 2023
Accepted: 13 August 2024
First Online: 26 September 2024
Competing interests
: J.R.C.-R. is a scientific consultant for NextRNA Therapeutics and Autoimmunity Biologic Solutions and holds patents on IRE1α modulation for the treatment of disease. O.E. is supported by Janssen, J&J, Astra-Zeneca, Volastra and Eli Lilly research grants. He is a scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and One Three Biotech and a paid scientific advisor to Champions Oncology and Pionyr Immunotherapeutics. The other authors declare no competing interests.